ANIK (Anika Therapeutics) EBIT per Share : $-2.13 (TTM As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Anika Therapeutics EBIT per Share?

Anika Therapeutics's EBIT per Share for the three months ended in Sep. 2024 was $-1.69. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-2.13.

During the past 3 years, the average EBIT per Share Growth Rate was -19.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Anika Therapeutics's EBIT per Share or its related term are showing as below:

ANIK' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -448.5 Med: 6.05 Max: 106.9
Current: -19.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Anika Therapeutics was 106.90% per year. The lowest was -448.50% per year. And the median was 6.05% per year.

ANIK's 3-Year EBIT Growth Rate is ranked worse than
83.45% of 828 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs ANIK: -19.50

Anika Therapeutics's EBIT for the three months ended in Sep. 2024 was $-24.9 Mil.

Anika Therapeutics EBIT per Share Historical Data

The historical data trend for Anika Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics EBIT per Share Chart

Anika Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

2.38

-1.02

-1.26

-1.33

-1.74

Anika Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.52	-0.11	-0.34	0.01	-1.69

Anika Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Anika Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-25.449	/	14.656
=	-1.74

Anika Therapeutics's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.916	/	14.768
=	-1.69

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.13

Anika Therapeutics (NAS:ANIK) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Anika Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Anika Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anika Therapeutics Inc (NAS:ANIK) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AKP:Germany AKP:Germany

Address

32 Wiggins Avenue, Bedford, MA, USA, 01730

Website

https://www.anika.com

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Executives

Anne Nunes	officer: SVP, Chief Operations Officer	32 WIGGINS AVENUE, BEDFORD MA 01730
Gary P Fischetti	director	600 TECHNOLOGY PARK DRIVE, 4TH FLOOR, BILLERICA MA 01821
David Colleran	officer: EVP, General Counsel, Corp Sec	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Michael L Levitz	officer: EVP, CFO, Treasurer	C/O ANALOGIC CORPORATION, 8 CENTENNIAL DRIVE, PEABODY MA 01960
Sheryl L Conley	director	C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond J Land	director
Stephen Richard	director	C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
James Loerop	officer: EVP Business Development	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Sylvia Cheung	officer: CFO	ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD MA 01730
Glenn R. Larsen	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Joseph I Bower	director	32 WIGGINS AVENUE, BEDFORD MA 01730
Jeffery S Thompson	director	1140 HAVENBROOK COURT, SUWANEE GA 30024
Joseph G Darling	officer: President	501 MANDALAY AVE., UNIT 409, CLEARWATER BEACH FL 33767